| News
Roche and Novartis among global leaders for research spending
05.05.2023
In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in 8th place worldwide. For its part, Novartis is ranked 14th, making it the second-highest ranking Swiss firm in the top 500.

In total, 14 Swiss companies are ranked in the group of 500 companies worldwide with the highest level of corporate expenditure for research and development (R&D), further details of which can be found in a press release issued by EY. With Roche ranked in 8th position overall, Switzerland is even represented in the top ten. Overall, the Basel-based pharmaceutical company invested the equivalent of 16 billion euros in R&D activities in 2022.
With Novartis in 14th position, the second-highest ranked Swiss firm also comes from Basel. The life sciences company spent the equivalent of 9.5 billion euros on R&D. At 159 million euros, the specialist chemicals firm Clariant from Muttenz in the canton of Basel-Landschaft was ranked in 454th place, making it the third Basel Area company in the top 500. The Swiss delegation is rounded off by STMicroelectronics, Nestlé, ABB, TE Connectivity, Alcon Inc, Givaudan, The Swatch Group, Swisscom, Sika, Holcim and Schindler Holding, which are ranked between 103rd and 420th.
Swiss companies invested 33 billion euros in R&D
Measured by the number of companies, Switzerland is more or less on a par with the UK, the press release explains. “This is an expression of the strength of Switzerland as a research location”, Stefan Rösch-Rütsche, Country Managing Partner of EY in Switzerland, who concludes that this can in particular be attributed to “the availability of human resources in research and development and the proximity to the world’s leading technical universities”.
All in all, Swiss companies invested the equivalent of 33 billion euros in R&D activities overall in 2022. This puts Switzerland in 5th place in a global comparison. For Rösch-Rütsche, this is “a positive sign for Switzerland as a business location”. However, he also points out that investments in Switzerland have increased by just +5 percent, which is well below the global average of +14 percent.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Genedata expanding its user network
The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site...
Read MoreHow Moderna is growing in Switzerland
The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...
Read MoreSandoz decides on Basel for headquarters
Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...
Read MoreVectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read MoreRami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read More